As many investigational cell and gene therapies continue to advance and demonstrate their clinical and commercial potential, companies including smaller biotechnology firms and larger ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...

Krystal's Vyjuvek innovative gene therapy leads DEB treatment, overshadowing Abeona's Zevaskyn. Check out the comparison ...

Read all the stories you want.